Thea Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Thea Pharma is the U.S. commercial arm of the 150-year-old, family-led global ophthalmology leader Laboratoires Théa. Founded in 2019, the company leverages its parent's deep expertise to bring preservative-free ophthalmic treatments and innovative delivery systems to the American market. It operates as a private, commercial-stage company with a focus on education, innovation, and professionalism in eye care. Its core mission is to address unmet needs in anterior segment and ocular surface diseases.

OphthalmologyOcular Surface DiseaseAnterior Segment Disease

Technology Platform

Expertise in preservative-free ophthalmic formulations and innovative drug delivery systems (e.g., single-dose units, multi-dose bottles with non-preservative antimicrobial technology).

Opportunities

The growing demand for preservative-free eye care products in the large U.S.

market presents a major opportunity.

Leveraging the strong legacy and proven portfolio of its parent company allows for rapid market entry and credibility with clinicians.

Risk Factors

Key risks include intense competition in the U.S.

ophthalmology market, potential challenges in securing favorable insurance reimbursement, and complete dependency on the parent company for product supply and pipeline development.

Competitive Landscape

Thea Pharma competes with large pharmaceutical companies (e.g., Novartis/Alcon, AbbVie/Allergan, Bausch + Lomb) and specialty pharma players in ophthalmology. Its primary differentiation is its focused expertise and leadership in preservative-free formulations, a niche where it holds a strong global reputation.

More companies in Small Molecule Drugs →More companies in United States →